Searched for
SUMITOMO PHARMA
Positive Breakout: These 11 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily time frame, it is generally considered to be an overall uptrend.- El Nino impact: Which stocks will burn & which will fire up as market braces for heat waveIndia faces a strong El Niño, threatening below-normal rainfall and impacting agriculture. While rural-linked sectors like two-wheelers and...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...
- Global Markets | Japan's Nikkei climbs as AI optimism outweighs Mideast concernsJapanese stocks surged Monday, nearing a historic peak, fueled by booming AI sector enthusiasm that overshadowed Middle East tensions. Majo...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe markets should be in a happy frame of mind till the time the current ceasefire in the Gulf region holds. Not many may like us using the...
- Global Markets | Japanese shares pare gains on doubts over Trump's Iran remarksJapanese shares pared gains on Tuesday as investors remained unconvinced that U.S. President Donald Trump's comments about holding off on t...
- Japan approves stem-cell treatment for Parkinson's in world firstPharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its Parkinson's disease t...
- Global Markets: Japanese shares dip as soft data, post-election lull cap movesJapanese shares drifted lower on Monday as weaker-than-expected economic data and a post-election lull capped moves.
- TrumpRx: Japanese drugmakers slump after Trump unveils discount drug websiteShares of Japanese pharmaceutical companies fell sharply in early Tokyo trading after the launch of TrumpRx, a U.S. website offering discou...
- Japan's Nikkei gauge trims 2025 surge as techs take a breatherJapan's Nikkei index saw a slight dip on Tuesday, with tech stocks leading the decline. Despite this, the Nikkei is on track for a signific...
- Japan's Topix posts record-high close despite US tariffs on pharmaJapan's broad Topix index closed at an all-time high on Friday, despite pressure from pharmaceutical shares following new tariffs on the se...
- Japan's Topix hits record high despite US tariffs on pharmaJapan's Topix index reached a record high on Friday. This happened despite pharmaceutical shares facing pressure. The Nikkei index, however...
- Japan's Nikkei treads water as central bank meetings, tariff deadline loomNikkei remained stable as investors are cautious. Policy announcements from the Federal Reserve and Bank of Japan are expected. Trump's tra...
- Nikkei rebounds as Fed's shift calms nerves; gains 3.8% in JanuaryFor the month, the Nikkei gained 3.8 per cent, after diving 10.5 per cent last month.
- Sumitomo Chemical to take majority stake in Excel Crop CarePursuant to the purchase of stakes from promoter and certain public shareholders, Sumitomo will make offer to the public to purchase up to ...
- Reliance Capital rallies 3% on stake sale reports to Sumitomo MitsuiThe deal signals bullishness among Japanese cos that seem keen to invest in sectors ranging from pharma to financial services in Asia's 3rd...
- Dr Reddy's Laboratories will infringe on Lunesta's patent: US court of appealThe United States Court of Appeals for the Federal Circuit has ruled that Dr Reddy's Laboratories Ltd will (rpt will) infringe on the paten...
- Dr Reddy's under pressure on losing appeal for LunestaDr Reddy's Laboratories were witnessing profit booking on reports that the company has lost a patent case for generic version of Lunesta.
- Lupin settles litigation over Lunesta with Japanese firmDrug firm Lupin on Monday said it has settled ongoing litigation over Lunesta tablets, used in treating insomnia, with Japan-based Dainippo...
Load More
